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Abstract
Background
Glycosylated hemoglobin A1c (HbA1c) has been proposed as an independent predictor of
long-term prognosis in pulmonary arterial hypertension. However, the clinical relevance of
HbA1c in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH)
remains unknown. The aim of the present study was to investigate the clinical significance
of HbA1c as a biomarker in CTEPH.
Methods
Prospectively, 102 patients underwent pulmonary endarterectomy (PEA) in our national
referral center between March 2013 and March 2014, of which after exclusion 45 patients
were analyzed. HbA1c- levels, hemodynamic and exercise parameters were analyzed prior
and one-year post-PEA.
Results
45 patients (BMI: 27.3 ± 6.0 kg/m2; age: 62.7 ± 12.3 years) with a mean pulmonary arterial
pressure (mPAP) of 43.6 ± 9.4 mmHg, a pulmonary vascular resistance (PVR) of 712.1 ±
520.4 dyn*s/cm5, a cardiac index (CI) of 2.4 ± 0.5 l/min/m2 and a mean HbA1c-level of 39.8
± 5.6 mmol/mol were included. One-year post-PEA pulmonary hemodynamic and functional
status significantly improved in our cohort. Baseline HbA1c-levels were significantly associ-
ated with CI, right atrial pressure, peak oxygen uptake and the change of 6-minute walking
distance using linear regression analysis. However, using logistic regression analysis base-
line HbA1c-levels were not significantly associated with residual post-PEA PH.
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Conclusions
This is the first prospective study to describe an association of HbA1c-levels with pulmonary
hemodynamics and exercise capacity in operable CTEPH patients. Our preliminary results
indicate that in these patients impaired glucose metabolism as assessed by HbA1c is of
clinical significance. However, HbA1c failed as a predictor of the hemodynamic outcome
one-year post-PEA.
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by unresolved pulmo-
nary vascular obstruction due to recurrent embolism, resulting in an increase in mean pulmo-
nary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) [1, 2]. The
progression of the disease is thought to be mainly caused by secondary small-vessel arteriopa-
thy in the non-obstructed areas and concomitant right ventricle (RV) dysfunction [1, 2].
Untreated, the disease may progress towards progressive right ventricle loading, hypertrophy
and failure [1, 2]. In case of surgically accessible CTEPH, pulmonary endarterectomy (PEA)
offers a potentially curative treatment with a high survival rate and an excellent long-term out-
come [3, 4]. However, residual post-PEA pulmonary hypertension (PH) has been recognized
as main determinant for mortality [5] and impaired exercise capacity [6]. Predictors of func-
tional outcome post-PEA are important in daily clinical practice. Therefore, identifying clini-
cally relevant biomarkers, which are indicative of the functional outcome after PEA, are of high
interest in operable CTEPH. Predictors of a favorable outcome post-PEA include pre-operative
forced expiratory volume in 1s (FEV1), heart-type fatty acid-binding protein (H-FABP) and
cardiac index (CI) [7, 8]. In most cases the residual PH results from a combination of concomi-
tant small vessel disease, incomplete removal of obstructions and varying degree of reverse
right ventricular remodeling after surgery [9]. Thus, the precise characterization of the contri-
bution of large and small vessel disease in CTEPH is mandatory for the indication and outcome
after PEA [10]. Recently, metabolic disorders have been identified as negative prognostic fac-
tors in pulmonary arterial hypertension (PAH) [11,12]. Interestingly, glycosylated hemoglobin
A1c (HbA1c) has been reported as a significant biomarker in PAH [11, 13] and insulin resis-
tance (IR) appears to be a risk factor and/or disease modifier that might impact survival in
PAH [14]. In the general population, increased HbA1c-levels are strongly associated with
microvascular complications [15]. The glycemic environment has been found to cause vascular
damage due to chronic inflammation, oxidative stress and endothelial dysfunction [16]. In
addition, non-diabetic hyperglycemia is an independent risk factor for cardiovascular disorders
[17]. Pathophysiological IR and dysregulated glucose metabolism may be modifiers of disease
in PH due to enhancement of inflammatory processes, dysregulation of the nitric oxide (NO)
pathway and endothelial damage [13, 18]. Therefore, we hypothesized that the concomitant
secondary small-vessel arteriopathy in CTEPH might be influenced by the glycemic environ-
ment and HbA1c-levels prior to PEA and might help to identify patients with a favorable func-
tional outcome post-PEA.
Methods
Patients
All CTEPH patients undergoing PEA between March 2013 and March 2014 at the Department
of Thoracic surgery, Kerckhoff-Clinic, Bad Nauheim, Germany were prospectively screened.
After exclusion, 45 patients with complete baseline and one-year post-PEA hemodynamic data
HbA1c in CTEPH
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were analyze (Fig 1). Baseline and follow-up right heart catheter (RHC) were not mandatorily
performed in-house, as the Kerckhoff-Clinic is a national referral center. Patients with symp-
tomatic chronic thromboembolic disease and mean pulmonary artery pressure <25 mmHg at
baseline were excluded [19] (Fig 1). Patients with a known history of diabetes mellitus or use of
anti-diabetic treatment were excluded. All included patients gave written, informed consent,
and the study was approved by the by the ethics committee of the Faculty of Medicine at the
University of Giessen (Approval No. 31/13).
All CTEPH patients were diagnosed according to current guidelines at that time [20] and a
multidisciplinary board including pulmonary physicians, PEA surgeons and pulmonary radiol-
ogists assessed operability. At inclusion, all patients had received oral anticoagulants for at least
3 months. All patients underwent PEA according to the protocol of the Kerckhoff-Clinic [21]
and treatment with targeted PAH therapy was permitted without restrictions. Residual PH one
year post PEA was defined by mPAP>25 mmHg and PVR> 240 dynes/cm5 at rest [6] while
the CTEPH type was classified by the surgical specimen as described previously [22].
Fig 1. Flow chart of patient selection. RHC: right heart catheterization; PEA: pulmonary endarterectomy; PH: pulmonary hypertension.
doi:10.1371/journal.pone.0152580.g001
HbA1c in CTEPH
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HbA1c testing
Venous blood samples were collected at the time of initial referral and were immediately ana-
lyzed in the laboratory of the Kerckhoff-Clinic.
HbA1c-levels were measured by Bio-Rad VARIANT™ II TURBO (Bio-Rad Laboratories,
Inc. Hercules, California, USA) with a reference range of 29–42 mmol/mol. In addition, fasting
plasma glucose, N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) and
serum creatinine were measured. Glomerular filtration rate was calculated using the Chronic
Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation [23].
The investigator who determined HbA1c was unaware of the patient baseline parameters or
clinical course and HbA1c-levels were not used to guide patient management or monitor the
effects of treatment during the study period.
Baseline parameters
Hemodynamic, 6-minute walk test (6MWT), echocardiography and cardio-pulmonary exer-
cise testing (CPET) data from all included patients were collected before and after PEA. Right
heart catheter (RHC) at baseline and follow-up were performed according current recommen-
dations at that time [20]. However, as the Kerckhoff-Clinic is a national referral center, RHC
were partly performed at referring centers. All patients performed a symptom-limited incre-
mental CPET using a ramp protocol with an incremental rate of 5 to 15 W/min judged by the
operator (Masterscreen1, Carefusion1) [24]. In all patients 6MWT was performed according
to current guidelines and patients were instructed to walk at their own pace along a 30-m corri-
dor while standard phrases were communicated [25]. Pulmonary artery systolic pressure
(PASP) and tricuspid annular plane systolic excursion (TAPSE) were assessed by right heart
echocardiography as described previously [26].
Statistical analysis
Data are presented as mean ± standard deviation for normally distributed parameters. As
appropriate the 2-tailed T-test, paired T-test, Mann-Whitney-U-test, Wilcoxon Signed Rank
test or Pearson Chi-Square test was used to test for differences between groups. HbA1c was
dichotomized at the cut-off indicative for the diagnosis of diabetes (47.5 mmol/mol) and of
pre-diabetes (39 mmol/mol) as stated in the position statement of the American Diabetes Asso-
ciation (ADA) [27]. Linear regression analysis was used to assess associations of HbA1c with
clinical parameters. All baseline parameters were analyzed in a univariate logistic regression
model with residual PH as dependent variable. Then, backward stepwise multivariate logistic
regression models were used to predict residual PH one-year post-PEA, considering all param-
eters of the univariate analysis with a p-value<0.15. Statistical analysis was performed using
SPSS, version 21.0 (IBM, Armonk, NY).
Results
Baseline
45 CTEPH patients with a mean age of 62.7 ± 12.3 years and a mean body mass index of
27.3 ± 6.0 kg/m2 were included. Patients presented mostly in WHO functional class III with an
impaired exercise capacity. At mean they had severe precapillary pulmonary hypertension with
a mPAP of 43.6 ± 9.4 mmHg, PAWP of 9.9 ± 5.3 mmHg, PVR of 712.1 ± 520.4 dynes/cm5
and a substantially reduced CI. Right heart echocardiography showed an elevated PASP of
75.4 ± 24.1 mmHg and a reduced TAPSE of 17.6 ± 5.0 mm. At baseline the HbA1c was
39.8 ± 5.6 mmol/mol and NT-proBNP-levels were significantly elevated while GFR and serum
HbA1c in CTEPH
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creatinine were within the normal range. At time of inclusion 15 patients received monother-
apy with pulmonary vasoactive therapies, mostly with phosphodiesterase type-5 inhibitors
(Table 1).
Table 1. Baseline characteristics.
Baseline One-year post-PEA
Patients, n 45
Male/Female 20/25
Age (y) 62.7 ± 12.3
BMI (kg/m2) 27.3 ± 6.0
Laboratory
HbA1c (mmol/mol) 39.8 ± 5.6 39.5 ± 4.4
GFR (l/min/m2) 81.9 ± 24.3 74.7 ± 25.1
Creatinine (mg/dl) 0.96 ± 0.3 0.99 ± 0.33
Fasting plasma glucose (mg/dl) 103.8 ± 30.4 102.1 ± 17.2
NT-proBNP (pg/ml) 966.0 [298.7–2286.3] 299.0 [124.0–474.7] #
Hb (g/l) 14.5 ± 1.8 13.4 ± 1.8**
Hct (%) 42.9 ± 5.0 41.7 ± 4.6
WHO functional class, n (%) ‡t16
I None 7 (15.6)
II 9 (20) 20 (44.4)
III 28 (62.2) 9 (20)
IV 8 (17.8) None
RHC
mPAP (mm Hg) 43.6 ± 9.4 28.5 ± 10.4*
RAP (mm Hg) 6.7 ± 3.4 6.5 ± 3.7
PVR (dyne*s/cm5) 712.1 ± 520.4 314.9 ± 233.7*
CI (l/min/m2) 2.4 ± 0.5 2.6 ± 0.6***
PAWP (mm Hg) 9.9 ± 5.3 10.8 ± 4.4
Echocardiography
TAPSE (mm) 17.6 ± 5.0 17.1 ± 3.2
PASP (mm Hg) 75.4 ± 24.1 54.2 ± 22.4*
6MWD (m) 362.2 ± 133.9 434.7 ± 124.5*
VO2 peak (ml/min/kg) 12.4 ± 4.1 14.2 ± 3.9****
Co-morbidities, n (%)
Dyslipidemia 5 (11.1) Unchanged
Metabolic syndrome 5 (11.1) Unchanged
Hypertension 23 (51.1) Unchanged
Coronary heart disease 6 (13.3) Unchanged
Renal insufﬁciency 8 (17.8) Unchanged
Pulmonary vasoactive therapies, n (%)
Phosphodiesterase type-5 inhibitors 11 (24.4) 1 (2.2)
Endothelin receptor antagonists 3 (6.7) None
Prostanoids 1 (2.2) None
Soluble guanylate cyclase stimulator None 8 (17.8)
No pharmacological treatment 30 (66.7) 36 (80)
Jamieson-Type [22], n (%) ‡‡
I 16 (37.2)
(Continued)
HbA1c in CTEPH
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One-year post pulmonary endarterectomy outcome
One-year post-PEA functional and hemodynamic parameters significantly improved and most
patients were in WHO functional class II (44.4%). HbA1c, Glucose and serum creatinine
remained unchanged while NT-proBNP and Hb were significantly reduced (Table 1). Residual
PH was found in 24 patients with significantly elevated mPAP, PVR and NT-proBNP in com-
parison with non PH. In addition, a higher percentage of patients with residual PH presented
in WHO functional class III and were treated notably with soluble guanylate cyclase stimula-
tors (Table 2). No differences in HbA1c, Glucose or serum creatinine were evident in compari-
son of patients with residual and non-residual PH.
Clinical relevance of HbA1c
Analyzing baseline characteristics were either dichotomized at HbA1c-level of 47.5 mmol/mol
indicative of diabetes or 39 mmol/mol indicative of pre-diabetes [27]. Exercise capacity was
more severely impaired in patients with HbA1c-levels> 47.5 mmol/mol displayed by a signifi-
cantly lower peak VO2. Moreover, these patients had a slight but insignificant enhanced
impairment of renal function. Interestingly, patients with HbA1c-levels> 39 mmol/mol
and> 47.5 mmol/mol showed significant higher RAP in comparison (Table 3).
Baseline HbA1c levels were correlated with baseline CI (r = 0.47, p = 0.001), RAP (r = 0.37,
p = 0.023) and peak VO2 (r = 0.39, p = 0.015) (Fig 2). There were no significant associations
between TAPSE (r = 0.28, p = 0.08), PASP (r = 0.11, p = 0.49), 6MWD (r = 0.10, p = 0.54) and
other baseline parameters (S1 Table). In addition, baseline HbA1c-levels were significantly
associated with the change of 6MWD (r = 0.32, p = 0.03; Fig 3) albeit not with the change of
mPAP (r = 0.05, p = 0.75), PVR (r = 0.19, p = 0.23), CI (r = 0.28, p = 0.07) one-year post-PEA.
Moreover, we analyzed patients without residual PH one-year post-PEA separately. In this
cohort HbA1c was significantly associated with TAPSE one-year post-PEA (S2 Table).
Univariate logistic regression analysis revealed that baseline HbA1c-levels were not associ-
ated with the presence of residual PH one-year post-PEA (p = 0.22). Additional multivariate
analysis including all parameters with p-value<0.15 of the univariate analysis and HbA1c
(albeit not significant in the univariate model) revealed that HbA1c was not related to the
hemodynamic outcome one-year post-PEA with a HR of 0.91 (95% CI for HR 0.76–1.01,
p = 0.31). The multivariate analysis identified baseline peak VO2 as a significant predictor of
Table 1. (Continued)
Baseline One-year post-PEA
II 10 (22.2)
III 17 (37.8)
Values represent mean ± SD or median [IQR]. CI: cardiac index, mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; RAP:
right atrial pressure, PAWP: pulmonary arterial wedge pressure, TAPSE: tricuspid annular plane systolic excursion; PASP: pulmonary artery systolic
pressure; 6MWD: six-minute walking distance; GFR: Glomerular ﬁltration rate; HbA1c: Glycosylated hemoglobin A1c; VO2: oxygen uptake WHO: World
Health Organization; NT-proBNP: N-terminal fragment of pro-brain natriuretic peptide; Hb: haemoglobin; Hct: haematocrit.
*p<0.001
**p = 0.003
***p = 0.04
****p = 0.04
# p = 0.002 versus baseline. (* = paired T-test, # = Wilcoxon Signed Rank test)
‡n = 36
‡‡n = 43.
doi:10.1371/journal.pone.0152580.t001
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residual PH with a HR of 0.78 (95% CI for HR 0.62–0.99, p = 0.04), while other parameters
failed to serve as independent predictors of the functional outcome one-year post-PEA in the
stepwise backward multivariable model (Table 4).
Table 2. Parameters one-year post-PEA according to residual PH.
non PH residual PH
Patients, n (%) 21 (46.7) 24 (53.3)
Laboratory
HbA1c (mmol/mol) 37.6 ± 2.9 40.9 ± 4.8
GFR (l/min/m2) 81.1 ± 23.3 70.0 ± 25.8
Creatinine (mg/dl) 0.95 ± 0.28 1.03 ± 0.36
Fasting plasma glucose (mmol) 104.9 ± 22.4 100.1 ± 12.5
NT-proBNP (pg/ml) 217.0 [38–472.5] # 389.9 [297.8–1077.6]
Hb (g/l) 13.9 ± 1.2 13.1 ± 2.1
Hct (%) 41.9 ± 2.7 41.6 ± 5.9
WHO functional class, n (%) ‡ † ‡‡
I 5 (31.3) 2 (10)
II 11 (68.7) 9 (45)
III None 9 (45)
IV None None
RHC
mPAP (mm Hg) 20.3 ± 2.8* 35.7 ± 9.2
RAP (mm Hg) 5.2 ± 2.4** 7.6 ± 4.2
PVR (dyne*s/cm5) 170.5 ± 57.8* 435.3 ± 257.1
CI (l/min/m2) 2.8 ± 0.6 2.5 ± 0.6
PAWP (mm Hg) 9.2 ± 3.2** 12.2 ± 4.8
Echocardiography
TAPSE (mm) 17.3 ± 3.0 16.9 ± 3.4
PASP (mm Hg) 43.0 ± 18.0 59.0 ± 22.9
6MWD (m) 478.8 ± 129.7 406.1 ± 115.4
VO2 peak (ml/min/kg) 15.5 ± 3.8 13.0 ± 3.7
Pulmonary vasoactive therapies, n (%) None 9 (37.5)
Phosphodiesterase type-5 inhibitors None 1 (4.2)
Soluble guanylate cyclase stimulator None 8 (33.3)
Jamieson-Type [22], n (%) Ұ ҰҰ
I 6 (30) 10 (43.5)
II 4 (20) 6 (26.1)
III 10 (50) 7 (30.4)
Values represent mean ± SD or median [IQR]. For abbreviations see Table 1.
*p<0.001
**p = 0.02
***p = 0.023
****p = 0.004
#p = 0.026
†p = 0.006, versus residual PH (* = 2-tailed T-test, # = Man-Whitney-U-test, † = Pearson Chi-Square test)
‡n = 16
‡‡n = 20
Ұn = 20
ҰҰn = 23.
doi:10.1371/journal.pone.0152580.t002
HbA1c in CTEPH
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Discussion
The present study prospectively evaluated HbA1c as a biomarker in a selected cohort of opera-
ble CTEPH patients and investigated its association with the outcome one-year post-PEA. An
association of HbA1c with baseline hemodynamic parameters and exercise capacity was found.
However, baseline HbA1c levels did not predict the hemodynamic outcome one-year post-
PEA.
Our study included operable CTEPH patients with severely impaired pulmonary hemody-
namics and low exercise capacity mostly in WHO functional class III. Hemodynamic parame-
ters and exercise capacity of our cohort mirrored the typical findings of patients with operable
CTEPH prior to PEA with a substantial impairment of right ventricular function as well as ele-
vated PVR, mPAP and reduced CI [28–32]. One-year post-PEA hemodynamic parameters,
exercise capacity and Nt-proBNP improved significantly, albeit 25 patients (49%) of our cohort
Table 3. Baseline Parameters according to HbA1c dichotomized at the cut-off indicative of diabetes or prediabetes according to the American Dia-
betes Association [27].
HbA1c  47.5 mmol/mol HbA1c > 47.5 mmol/mol HbA1c  39 mmol/mol HbA1c > 39 mmol/mol
Patients, n (%) 40 (89) 5 (11) 21 (47) 24 (53)
Laboratory
HbA1c (mmol/mol) 38.4 ± 4.1* 51.0 ± 1.9 35.4 ± 2.7† 43.7 ± 4.5
GFR (l/min/m2) 83.4 ± 24.1 69.4 ± 25.5 88.9 ± 25.0 75.7 ± 22.5
Creatinine (mg/dl) 0.92 ± 0.29 1.1 ± 0.43 0.86 ± 0.23 1.02 ± 0.35
Fasting plasma glucose (mmol) 99.2 ± 24.4** 141.2 ± 48.8 95.0 ± 16.6 111.8 ± 37.2
NT-proBNP (pg/ml) 746.5 [284.0–1847.0] 3412 [1436.2–5021.5] 512.6 [175.0–1337.5] 1808 [425.2–3101.0]
Hb (g/l) 14.6 ± 1.7 14.1 ± 2.7 14.5 ± 1.9 14.5 ± 1.8
Hct (%) 43.3 ± 5.2 43.1 ± 6.4 42.9 ± 5.3 43.5 ± 5.2
WHO functional class, n (%)
II 9 (22.5) none 4 (19) 5 (21)
III 25 (62.5) 3 (60) 14 (66.7) 14 (58)
IV 6 (15) 2 (40) 3 (14.3) 5 (21)
RHC
mPAP (mm Hg) 43.3 ± 9.0 45.6 ± 13.3 44.3 ± 8.7 42.9 ± 10.1
RAP (mm Hg) 6.4 ± 3.1*** 11.0 ± 4.6 5.6 ± 2.2††† 7.9 ± 4.1
PVR (dyne*s/cm5) 698.9 ± 505.7 729.4 ± 441.6 582.8 ± 197.2 818.9 ± 668.3
CI (l/min/m2) 2.4 ± 0.5 2.0 ± 0.5 2.6 ± 0.5†† 2.2 ± 0.5
PAWP (mm Hg) 9.7 ± 4.7 12.5 ± 10.3 9.5 ± 5.3 10.3 ± 5.5
Echocardiography
TAPSE (mm) 17.6 ± 4.7 17.3 ± 8.5 18.7 ± 4.6 16.6 ± 5.3
PASP (mm Hg) 76.3 ± 22.9 68.3 ± 36.3 69.7 ± 23.3 79.8 ± 24.3
6MWD (m) 374.6 ± 133.6 265.0 ± 98.2 343.6 ± 127.0 377.6 ± 140.1
VO2 peak (ml/min/kg) 12.9 ± 4.0**** 8.8 ± 2.8 13.2 ± 3.5 11.8 ± 4.5
Values represent mean ± SD or median [IQR]. For abbreviations see Table 1.
*p<0.001
**p = 0.003
***p = 0.02
****p = 0.035 versus HbA1c > 47.5 mmol/mol
†p<0.001
††p = 0.02
†††p = 0.03 versus HbA1c > 39 mmol/mol (* and † = 2-tailed T-test).
doi:10.1371/journal.pone.0152580.t003
HbA1c in CTEPH
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Fig 2. Associations between baseline HbA1c and CI (r = 0.47, p = 0.001) (A), RAP (r = 0.37, p = 0.023)
(B) and peak VO2 (r = 0.39, p = 0.015) (C). For abbreviations see Table 1.
doi:10.1371/journal.pone.0152580.g002
HbA1c in CTEPH
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exhibited a residual PH. In line with previously published data a significant improvement of
the functional outcome one-year post-PEA was observed [3, 4]. However, as described in our
study, the individual outcome after PEA differed with 10% to 24% of patients remaining symp-
tomatic [4, 33] and up to 35% were presenting with residual PH [6, 30, 34]. The established
Fig 3. Association between baseline HbA1c-levels and the change of 6MWD (r = 0.32, p = 0.03). For
abbreviations see Table 1.
doi:10.1371/journal.pone.0152580.g003
Table 4. HbA1c levels and baseline parameters as predictors of residual PH one-year post-PEA.
Univariate model Multivariate model#
HR (95% CI) p-value HR (95% CI) p-value
HbA1c (mmol/mol) 1.07 [0.96–1.20] 0.22 - -
mPAP (mm Hg) 1.06 [0.99–1.14] 0.11 - -
RAP (mm Hg) 1.01 [0.84–1.23] 0.89 - -
PVR (dyne*s/cm5) 1.00 [0.99–1.01] 0.92 - -
CI (l/min/m2) 0.50 [0.16–1.62] 0.25 - -
PAWP (mm Hg) 1.03 [0.92–1.16] 0.63 - -
TAPSE (mm) 0.89 [0.77–1.02] 0.09 - -
PASP (mm Hg) 1.02 [0.99–1.05] 0.17 - -
VO2 peak (ml/min/kg) 0.78 [0.62–0.98] 0.03 0.78 [0.62–0.99] 0.04
6MWD (m) 0.99 [0.99–1.02] 0.25 - -
Nt-pro BNP (pg/ml) 1.00 [1.00–1.01] 0.43 - -
WHO functional class - -
II Reference - -
III 2.31 [0.48–11.12] 0.30 - -
IV 6.00 [0.72–49.84] 0.10 - -
Jamieson-Type [22] 0.65 [0.32–1.3] 0.22 - -
Hb (g/l) 1.06 [0.76–1.46] 0.74 - -
Hct (%) 1.03 [0.92–1.16] 0.60 - -
Fasting plasma glucose (mmol) 1.03 [1.0–1.07] 0.07 - -
HR: hazard ratio; CI: conﬁdence interval; For abbreviations see Table 1.
#: backward stepwise logistic regression including variables with a p-value <0.15 in the univariate model.
doi:10.1371/journal.pone.0152580.t004
HbA1c in CTEPH
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diagnosis of diabetes mellitus type II was present in 6 patients, which were excluded from the
analysis. Nevertheless, the low prevalence of established diagnosis of diabetes type II in our
cohort is in accordance with international registry data reporting diabetes type II in approxi-
mately 5.3% of CTEPH patients [35]. However, using the ADA criteria 5 additional patients
who did not have the diagnosis of diabetes mellitus yet, presented with indicative high HbA1c-
levels> 47.5mmol/mol.
Interestingly, our data indicated for the first time that HbA1c-levels prior to PEA correlated
with baseline RAP, CI and peak VO2 in operable CTEPH patients, although similar hemody-
namic parameters (apart from RAP) and RV systolic function were found in comparison of
low HbA1c-levels (< 47.5mmol/mol) with elevated HbA1c-levels. In addition, patients with
HbA1c levels> 39 mmol/mol [27], presented with a further impaired CI and higher RAP in
comparison. The significant association of HbA1c with baseline RAP in CTEPH underlines the
presence of diastolic dysfunction due to stiffer right ventricles in a more profound glycemic
environment, as described for PAH patients previously [36]. In addition, impaired glucose
metabolism is potentially influencing CI in CTEPH by aggravating impaired myocardial relax-
ation and increased myocardial stiffness as seen in diabetic cardiomyopathy [37] or metabolic
disease in PAH [38]. Similar to our finding of an association of glucose intolerance in operable
CTEPH with worse exercise capacity as assessed by peak VO2, Pugh and coworkers demon-
strated a trend to a correlation of baseline HbA1c-levels with functional capacity (assessed by
6MWD) in PAH [13]. Moreover, our study showed a weak but significant association of
HbA1c-levels with the change of 6MWD one-year post-PEA. However, up to now, no robust
associations of the altered glucose metabolism and 6MWD have been reported in PH patients.
Zamanian and coworkers described no significant difference of the 6MWD between PAH
patients with and without IR [14]. Further, our data suggest that HbA1c is more elevated in
advanced disease, although differences in WHO functional class, mPAP and PVR were not sta-
tistically significant.
Despite these significant associations to baseline parameters, HbA1c was not significantly
correlated to outcome parameters post-PEA in univariate and multivariate analysis. One can
speculate that the influence of the glycemic environment pre-PEA on secondary small-vessel
arteriopathy and RV dysfunction plays only a minor role one-year post-PEA and/or is not
reflected by HbA1c directly. In addition, our cohort presented with predominantly proximal
disease as reflected by the absence of Jamieson-Type IV patients. Furthermore, the relatively
high number of residual PH in our study potentially results from incomplete removal of
obstructions and/or a varying degree of reverse right ventricular remodeling after surgery
rather than from concomitant small vessel disease. Thus, the prognostic impact of impaired
glucose metabolism as a solitary marker is comparably moderate. Other pre-operative predic-
tors of post-operative outcome such as mPAP [7], serum creatinine level, the number of
involved segments, PVR and gender [39] are useful complementary parameters to the currently
reported HbA1c-levels.
A limitation of our study is the lack of systematic evaluation post-PEA to differentiate
between non-removable material or secondary microvascular disease as major cause of residual
PH. In addition, register analysis featured an enhanced influence of diabetes as a risk factor in
IPAH patients rather than operable CTEPH [35]. Therefore, in case of inoperable CTEPH with
distal disease and pronounced secondary small-vessel arteriopathy the association of impaired
glucose metabolism assessed by HbA1c with pulmonary hemodynamics and long-term out-
come remains unknown and in need of further investigations. Pathophysiologically, the
obstructive remodeling of pulmonary arteries in CTEPH involves inflammation, in situ throm-
bosis and endothelial dysfunction [40]. Inflammatory mediators play a key role in the patho-
logical mechanisms of CTEPH partly mediating the obstructive remodeling of pulmonary
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arteries [40] and being associated with RV dysfunction [41]. Yet, cytokines have not been
linked to impaired glucose metabolism to date. However, in patients with PAH and idiopathic
PAH, albeit not in CTEPH, various studies have extensively analyzed the clinical relevance of
HbA1c and an association of impaired glucose metabolism with disease severity was found [11,
13, 36]. Moreover, IR has been identified as an important risk factor for disease progression
and is associated with a poorer survival in PAH [14]. IR is linked to pro-inflammatory cyto-
kines with significant contribution to the pathophysiology of PAH [14] and is associated with
the development of pulmonary vascular disease in mice [42]. Furthermore, animal models
have shown that impaired glucose metabolism and IR have a direct impact on the pulmonary
vasculature and the pulmonary smooth muscle cell (SMC) leading to higher RV pressures,
enhanced RV hypertrophy and peripheral pulmonary arterial muscularization [43]. In addi-
tion, the glycemic environment induces endothelial dysfunction with an impaired relaxant
response through dysregulations in the NO pathway in diabetic rats [44]. We did not asses IR
as our study was not designed to evaluate these parameter, therefore future trails addressing
this issue are warranted.
Limitations of the study are the moderate sample size, the lack of prospective inclusion of
inoperable CTEPH patients and the overall low prevalence of impaired glucose metabolism in
our cohort. As we are a national referral center, the one-year follow-up visit was not mandatorily
performed in our center and accounts for the dropout rate of 29 patients. In addition, the rate of
residual PH was higher than reported in the literature. The relatively high rate of residual PH is
not fully understood. The rate is influenced by many factors, including the type of pre-surgical
CTEPH (proximal vs. distal), the severity of pre-surgical PH (possible reflection of micro-vascu-
lar disease) and the different underlying confounders that lead to CTEPH (e.g. simple recurrent
deep vein thrombosis and pulmonary embolism vs. splenectomy vs. infected pacemaker leads
etc.). We also believe that the selection criteria for the current observation might result in an
enrichment of patients who are prone to have a comparably high proportion of residual PH after
surgery. Lastly, a selection bias might have played a role, in that patients with residual PH (i.e.
symptomatic patients) are more likely to be followed up by means of RHC.
Conclusions
In conclusion, this is the first study to describe an association of HbA1c-levels with pulmonary
hemodynamic parameters and exercise capacity in a selected cohort of operable CTEPH
patients. Our preliminary results indicate that in these patients impaired glucose metabolism
as assessed by HbA1c is of clinical significance. However, HbA1c did not predict hemodynamic
outcome one-year post-PEA in our cohort.
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